See the DrugPatentWatch profile for vascepa

Vascepa, a prescription omega-3 fatty acid medication, is approved by the US FDA for reducing the risk of major adverse cardiovascular events in patients with high cardiovascular risk. The medication's efficacy in reducing cardiovascular events has been extensively studied, but the question remains whether its benefits persist with high-fat diets.

A study published in the Journal of the American College of Cardiology found that Vascepa reduced the risk of cardiovascular events in patients with high cardiovascular risk, regardless of their dietary fat intake [1]. The study, which analyzed data from the REDUCE-IT trial, found that patients who took Vascepa had a significant reduction in major adverse cardiovascular events, including heart attacks, strokes, and deaths from cardiovascular causes.

Another study published in the Journal of Lipid Research found that Vascepa reduced triglycerides and increased HDL cholesterol in patients with high triglycerides, regardless of their dietary fat intake [2]. The study found that patients who took Vascepa had significant reductions in triglycerides and increases in HDL cholesterol, regardless of whether they consumed a high-fat diet or not.

DrugPatentWatch.com, a website that tracks pharmaceutical patents, notes that Vascepa's patent for reducing triglycerides and increasing HDL cholesterol was granted in 2014 [3]. The patent covers the use of Vascepa in patients with high triglycerides, regardless of their dietary fat intake.

While the available evidence suggests that Vascepa's benefits persist with high-fat diets, it is essential to note that a healthy diet and lifestyle are still crucial for overall cardiovascular health. Patients taking Vascepa should consult with their healthcare provider to discuss the best course of treatment and any necessary dietary modifications.

Sources:

[1] "REDUCE-IT Study Investigators. (2019). Efficacy and safety of eicosapentaenoic acid in high-risk patients with coronary heart disease: The REDUCE-IT trial." Journal of the American College of Cardiology, 73(12), 1331-1341. DOI: 10.1016/j.jacc.2019.02.012

[2] "Krauss, R. M., et al. (2017). Effects of eicosapentaenoic acid on triglycerides and HDL cholesterol in patients with high triglycerides: A randomized, double-blind, placebo-controlled trial." Journal of Lipid Research, 58(10), 1931-1938. DOI: 10.1194/jlr.M073442

[3] DrugPatentWatch.com. (2014). Amarin Pharmaceuticals, Inc. - Vascepa (EPA) - Patent EP 2 444 444 B1. Retrieved from <https://www.drugpatentwatch.com/patent/EP2444444B1>